HOME >> BIOLOGY >> NEWS
Clemson University delivers healthy mares and foals

CLEMSON - A medication used to treat nausea is now helping horse breeders produce healthier mares and foals and may someday help address problems of infertility in humans. Dee L. Cross, a Clemson University animal scientist, hypothesized that the medication, now patented as Equidone, could be useful in treating a condition called fescue toxicosis in pregnant mares.

Fescue toxicosis is caused by a fungus that infects fescue grass pastures and results in severe reproductive problems, including spontaneous abortions, prolonged pregnancy, difficulty giving birth and no milk production. Many times the foal is stillborn or dies shortly after birth; the mare can also die or have to be destroyed because of complications during delivery.

In the horse racing industry, where stud fees are measured in six figures and sale prices can reach several million dollars, there is little margin for error in breeding programs. Aside from the investment aspect, both professional breeders and private individuals want to protect the health and well-being of their horses.

"We studied the cellular action of the alkaloids produced by the fungus-infected fescue grass," Cross said. "The alkaloids were activating dopamine receptors that this drug was known to block when used to give relief from nausea in humans."

The researchers tested their theory in the laboratory and found that Equidone did in fact block the activity of alkaloids extracted from the contaminated grass. They then moved to testing the treatment on horses grazing on fescue pastures and got positive results in the very first study.

The medication is now being tested by veterinarians around the country under an experimental permit from the federal Food and Drug Administration.

The results are very promising. Mares treated with the medication for 10-15 days before their anticipated foaling date are delivering healthy foals without complications and producin
'"/>

Contact: Dee Cross
dcross@clemson.edu
864-656-5155
Clemson University
19-Jul-1999


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson researcher receives Komen grant
4. Clemson University researcher reaches for the stars to prevent osteoporosis
5. Clemson launches S.C. DNA Learning Center
6. Clemson dedicates biotech research complex
7. Breakthrough Clemson research appears in Science
8. Clemson researcher takes part in breakthrough research on insects
9. Clemson researchers find bacteria fighter that does not promote bacterial resistance
10. Clemson researchers identify mental retardation gene
11. Clemson researchers create biosensors to protect nations food and water supplies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/23/2020)... ... 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical company focused ... an Investigational New Drug application (IND) with the U.S. Food & Drug Administration ... NBTX-001 in patients with panic disorder (PD). , "Adding a PD trial to ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
Breaking Biology Technology:
Cached News: